User:Mr. Ibrahem/Letermovir

Letermovir, sold under the brand name Prevymis, is an antiviral medication used to prevent cytomegalovirus (CMV) reactivation following allogeneic stem cell transplant. It is used in those who are seropositive for CMV. It may be taken by mouth or injection into a vein.

Common side effects include nausea, diarrhea, and vomiting. Other side effects may include swelling, cough, headache, and tiredness. It is a cytomegalovirus DNA terminase complex inhibitor.

Letermovir was approved for medical use in the United States in 2017 and Europe in 2018. In the United Kingdom it costs the NHS about £7,500 for 4 weeks as of 2021. This amount in the United States is about 6,200 USD.